Beihui Huang

500 total citations
59 papers, 350 citations indexed

About

Beihui Huang is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Beihui Huang has authored 59 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 37 papers in Molecular Biology and 32 papers in Oncology. Recurrent topics in Beihui Huang's work include Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (13 papers). Beihui Huang is often cited by papers focused on Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (13 papers). Beihui Huang collaborates with scholars based in China. Beihui Huang's co-authors include Junru Liu, Juan Li, Zheng Dong, Juan Li, Zhenhai Zhou, Chang Su, Juan Li, Bingqing Zhang, Jingli Gu and Ying Li and has published in prestigious journals such as Blood, Biochemical and Biophysical Research Communications and Annals of Oncology.

In The Last Decade

Beihui Huang

50 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beihui Huang China	11	200	188	120	74	43	59	350
Amr Hanbali United States	9	108 0.5×	104 0.6×	74 0.6×	26 0.4×	57 1.3×	43	301
Chang Ki Min South Korea	11	125 0.6×	177 0.9×	163 1.4×	64 0.9×	15 0.3×	38	416
Shenglan Gong China	11	286 1.4×	180 1.0×	118 1.0×	67 0.9×	7 0.2×	30	447
Delphine Oguey Switzerland	10	68 0.3×	191 1.0×	56 0.5×	52 0.7×	38 0.9×	13	383
Maria Niniraki Greece	9	86 0.4×	127 0.7×	59 0.5×	47 0.6×	13 0.3×	12	335
Qitian Mu China	11	209 1.0×	127 0.7×	61 0.5×	40 0.5×	18 0.4×	61	370
Michelle E. Maglio United States	8	188 0.9×	215 1.1×	149 1.2×	21 0.3×	8 0.2×	9	359
José González Spain	10	365 1.8×	297 1.6×	99 0.8×	23 0.3×	10 0.2×	25	507
Tateru Ishida Japan	7	328 1.6×	74 0.4×	47 0.4×	59 0.8×	38 0.9×	11	509
Yu-Min Liao Taiwan	11	137 0.7×	60 0.3×	143 1.2×	239 3.2×	221 5.1×	15	539

Countries citing papers authored by Beihui Huang

Since Specialization

Citations

This map shows the geographic impact of Beihui Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beihui Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beihui Huang more than expected).

Fields of papers citing papers by Beihui Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beihui Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beihui Huang. The network helps show where Beihui Huang may publish in the future.

Co-authorship network of co-authors of Beihui Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Beihui Huang. A scholar is included among the top collaborators of Beihui Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beihui Huang. Beihui Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Beihui, et al.. (2025). Early Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram. Biomedicines. 13(1). 145–145.

Huang, Beihui, et al.. (2024). The identification and correction of pseudohypercalcemia. Frontiers in Oncology. 14. 1441851–1441851.

Liu, Junru, et al.. (2024). Early M‐protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high‐risk cytogenetic multiple myeloma. British Journal of Haematology. 204(3). 976–987. 2 indexed citations

Liu, Junru, et al.. (2024). Efficacy of prophylactic antibiotics for the prevention of neutropenic fever in patients with multiple myeloma receiving high-dose cyclophosphamide for stem cell mobilization. Annals of Hematology. 103(5). 1601–1611.

Liu, Junru, et al.. (2024). On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost. Frontiers in Oncology. 13. 1306367–1306367.

Huang, Beihui, et al.. (2024). Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period. Journal of Infection and Chemotherapy. 31(2). 102562–102562.

Huang, Beihui, et al.. (2023). RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells. Medical Oncology. 40(4). 115–115. 3 indexed citations

Liu, Junru, et al.. (2023). Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance. Journal of Personalized Medicine. 13(3). 412–412. 4 indexed citations

Liu, Junru, et al.. (2023). Prolonged infusion time of cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) as a mobilization regimen may improve mobilization efficiency in newly diagnosed multiple myeloma patients: a single center experience. Annals of Medicine. 55(2). 2289603–2289603.

10.

Chen, Yadong, et al.. (2023). Development and validation of a chemotherapy tolerance prediction model for Chinese multiple myeloma patients: The TM frailty score. Frontiers in Oncology. 13. 1103687–1103687. 2 indexed citations

11.

Liu, Junru, et al.. (2021). Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Cancer Medicine. 10(21). 7641–7649. 4 indexed citations

12.

Huang, Beihui, et al.. (2021). Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis. Journal of Cancer Research and Clinical Oncology. 148(4). 913–919. 5 indexed citations

13.

Xu, Limei, et al.. (2020). Early monoclonal protein decline pattern is an independent prognostic factor in patients with multiple myeloma. Annals of Hematology. 99(3). 581–589. 4 indexed citations

14.

Chen, Wen-Ming, Yin Wu, Jianyong Li, et al.. (2019). 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China. The Oncologist. 24(11). e1132–e1140. 20 indexed citations

15.

Liu, Junru, et al.. (2018). Longitudinal Flow Cytometry Identified “Minimal Residual Disease” (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma. Biology of Blood and Marrow Transplantation. 24(12). 2568–2574. 33 indexed citations

16.

Li, Juan, et al.. (2018). Investigation of the optimal duration of bed rest in the supine position to reduce complications after lumbar puncture combined with intrathecal chemotherapy: a multicenter prospective randomized controlled trial. Supportive Care in Cancer. 26(9). 2995–3002. 5 indexed citations

17.

Huang, Beihui & Juan Li. (2017). Positive Minimal Residual Disease By Multiparameter Flow Cytometry in 9 Months after Autologous Stem Cell Transplantation and High-Risk Cytogenetics Predict Poor Outcome in Multiple Myeloma. Blood. 130. 4532–4532. 1 indexed citations

18.

Huang, Beihui, et al.. (2015). CD20-positive multiple myeloma: can conventional chemotherapy still be used to achieve ideal outcome for these patients?. Leukemia & lymphoma. 57(2). 335–340. 5 indexed citations

19.

Huang, Beihui, et al.. (2014). Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD). Pathologie Biologie. 63(1). 17–20. 8 indexed citations

20.

Wang, Qing, Juan Li, Jingli Gu, et al.. (2009). Potentiation of (−)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells. Acta Biochimica et Biophysica Sinica. 41(12). 1018–1026. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact